The efficacy of ICI therapies, including the anti-CTLA4 (ipilimumab) and anti-PD-1 (nivolumab and pembrolizumab) monoclonal antibodies, is well established in patients with stage III/IV melanoma. This evidence concerns the gene PDCD1 and melanoma.